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1. Introduction
he catastrophic variant of  the antiphos-
pholipid syndrome (CAPS), which is also 
named as Asherson’s syndrome (1-4), is 
defined as a potential life-threatening variant of 
this syndrome, which is characterized by multiple 
small-vessel thrombosis that can lead to multi-
organ failure, particularly renal deterioration (2-
4). A renal small-vessel nephropathy, defined as 
antiphospholipid syndrome nephropathy (APS 
nephropathy; APSN), has been described (3,4). 
This vaso-occlusive disease mainly affects arte-
rioles, interlobular arteries and glomerular tufts. 
However, interstitial area and tubules may subse-
quently be involved (2-7).
2. Case
A 42-year-old woman was admitted in the
emergency ward because of  confusion which 
started five days ago. She had also suffered from 
nausea and vomiting. Patient was a passenger, 
who came from a neighboring province. On ex-
amination, a 160/90 mmHg of  arterial blood 
pressure, asterixis and fever was found. Other 
physical examinations were normal. In the past 
medical history, a history of  hypertension (under 
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treatment of  atenolol; 100 mg/day) for 10 years 
and psychiatric disturbance, bipolar type (which 
was under treatment of  Lithium carbonate, Car-
bamazepine and Amitriptyline) from 5 years 
ago were identified. Laboratory tests revealed 
anemia, elevated ESR (102 mm/1hr) and raised 
serum creatinine (10 mg/dL). Urinalysis showed 
mild proteinuria and pyuria. Ultrasonography 
showed normal size kidneys with  increased pa-
renchymal echogenicity. Urine protein excretion 
during 24 hours was 280 mg. With the primary 
diagnosis of  acute renal failure (ARF), hemodi-
alysis was started. Patient was also treated by ap-
propriate antibiotic and other supportive thera-
pies. Because, there was not any improvement 
after 18 days of  admission and with the primary 
impression of  acute tubular necrosis or inter-
stitial nephritis due to chronic Lithium therapy, 
patient underwent kidney biopsy. Light micro-
scopic examination disclosed global sclerosis 
in four out of  eight glomeruli and four a tuft 
glomeruli (glomerular ballooning). In glomeruli, 
no evidence of  hypercellularity, inflammation, 
necrosis and/or thrombosis was visualized. Se-
vere chronic interstitial inflammation accompa-
nied by fibrosis was also observed. Foci of  tubu-
lar thyroidization were also identified (figure.1A, 
B). Interlobular arteries revealed a constellation 
of  findings including fibrinoid necrosis, throm-
bosis with partial to complete luminal closure, 
onion skin appearance and vascular wall edema 
(figure.2A, B &C). Immunofluorescence study 
revealed positive immunoreactivity for IgM and 
C3 in mesangial area. The morphologic diagno-
sis was thrombotic microangiopathy. Further 
history taking revealed two episodes of  miscar-
riage (after six months of  pregnancy). Laborato-
ry evaluations revealed a positive anti-cardiolipin 
antibody (IgG, >40 U/mL). Other autoantibod-
ies consisting of  p-ANCA, c-ANCA, anti-nu-
clear antibody, anti-ds-DNA were negative. Se-
rum complement levels were also within normal 
limits. According to morphological, clinical and 
laboratory data, diagnosis of  APS nephropa-
thy was made. Anti-cardiolipin antibody (IgG) 
was retested after 14 weeks and continued to 
be positive, confirming catastrophic variant of 
the APSN. Patient was treated with intravenous 
heparin followed by oral Warfarin and also other 
supportive treatment, while hemodialysis and 
corticosteroids were continued due to persistent 
renal failure.  On further follow up, the patient 
remained dependent on dialysis in her province.
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Figure 1. A: Sever interstitial inflammation and fibrosis .B: 
tubular thyroidization  (H&E ×400).
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Figure 2 (A, B& C). A:Fibrinoid necrosis and thrombosis 
of  interlobular artery. B: Vascular wall edema. C: Fibrous 
intimal hyperplasia of  an interlobular artery, made aspect of 
onion skin pattern (H&E and PAS ×400).
3. Discussion
 APS is as an autoimmune disorder character-
ized by recurrent thrombosis and/or obstetrical 
morbidity (1-3). CAPS is the most severe form 
of  APS with acute multiple organ involvement 
and small vessel thrombosis (4-9). CAPS is an ac-
celerated variant of  APS, resulting in multi-organ 
failure due to extensive thrombosis formation (2-
4).The diagnosis of  this syndrome requires the 
presence of   clinical evidence of  involvement of 
three or more organs in a period of  less than a 
week, histopathological evidence of  small vessel 
occlusion in at least one organ, and  finally  labo-
ratory confirmation of  the presence of  antiphos-
pholipid antibodies (APAs), usually in high titer 
(2-6). CAPS represent less than 1% of  all patients 
with APS. However, they are usually in a life-
threatening situation and its potentially lethal out-
come emphasizes its importance in clinical medi-
cine today. The rarity of  this variant of  APSN 
makes it extraordinarily difficult to study in any 
systematic way (4-9). Early recognition of  APS is 
crucial, while  aggressive management can result 
in a favorable outcome (2-5). The recognized re-
nal manifestations of  this syndrome defined as 
APS nephropathy, are the renal artery thrombo-
sis/stenosis, renal vein thrombosis, renal infarc-
tion, end-stage renal disease, increased allograft 
vascular thrombosis, some types of  glomerular 
disease, hypertension  and thrombotic microangi-
opathy (TMA) (1,2,10-12). TMA is characterized 
by acute thrombotic lesions in glomeruli and/
or arterioles  and chronic vascular lesions such 
as fibrous intimal hyperplasia of  arterioles and 
interlobular arteries, organized thrombi with or 
without recanalization, and fibrous arterial and 
arteriolar occlusions or focal cortical atrophy 
(3-9). TMA is histological diagnosis and clinical 
differential diagnosis includes malignant hyper-
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tension, hemolytic uremic syndrome, throm-
botic thrombocytopenic purpura, disseminated 
intravascular coagulation, scleroderma, toxemia 
of  pregnancy and APS. The final diagnosis of 
APS can be made only if  patient have TMA plus 
clinical and laboratory data (anti-cardiolipin an-
tibody). The most frequent clinical and labora-
tory characteristics of  APSN are hypertension 
(often severe), proteinuria (ranging from mild to 
nephrotic range), hematuria, and acute or chronic 
renal insufficiency (12-14).
4. Conclusions
 The CAPS is a very rare complication encoun-
tered in a subset of  patients with APS. This rare 
syndrome is defined by the development of  mul-
tiple blood clots that block small blood vessels 
in several organs in the body. One of  the organs 
most commonly affected by these small blood 
clots includes kidneys so-called APS nephropathy.
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